Help us in celebrating Dr. Phil Huyett's 500th implant milestone and hear what he has to say about Inspire® therapy: “This milestone is a reflection of having the best clinical and surgical teammates over the last four years. What I am perhaps most proud of is that we provide both the surgical and medical management of this wonderful therapy for patients with obstructive sleep apnea." - Dr. Phil Huyett, Mass Eye and Ear. View important safety information at https://lnkd.in/gkej87Qx.
Inspire Medical Systems
Medical Equipment Manufacturing
Golden Valley, Minnesota 30,132 followers
We are committed to elevating and redefining the standard of care for Obstructive Sleep Apnea.
About us
Inspire Medical Systems, Inc. has developed the world’s first fully implanted neurostimulation device approved by the FDA for the treatment of Obstructive Sleep Apnea (OSA). The Inspire system uses well-established neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient’s unique breathing patterns. Inspire therapy is designed to reduce OSA severity and improve quality of life for patients living with this challenging condition.
- Website
-
http://www.inspiresleep.com
External link for Inspire Medical Systems
- Industry
- Medical Equipment Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Golden Valley, Minnesota
- Type
- Public Company
- Founded
- 2007
- Specialties
- Obstructive Sleep Apnea, ENT, sleep, patient engagement, digital health, medical device, medical devices, Sleep Apnea, Healthcare, health systems, and sleep disorders
Locations
-
Primary
5500 Wayzata Blvd
Suite 1600
Golden Valley, Minnesota 55416, US
Employees at Inspire Medical Systems
Updates
-
Karen Wolk was diagnosed with obstructive sleep apnea at 45. She tried different treatment options that didn’t help, but then she was introduced to Inspire® therapy, which allowed her to get restful sleep for the first time in decades. Check out her story with ABC10! Individual Results may vary. Inspire Upper Airway Stimulator: Moderate to severe OSA. RxOnly. Ages 18+. Failure of, or inability to use, CPAP required. For safety information, visit http://bit.ly/Safety-Info.
-
During Sleep Awareness Week, we're aware of the impact of sleep apnea, affecting roughly 1 in 15 Americans. As we celebrate World Sleep Day, we're excited to share a PBS documentary, shedding light on untreated sleep apnea risks, traditional sleep apnea treatments, and the entire Inspire process. We are grateful for the opportunity to help over 60,000 patients treat their sleep apnea with Inspire therapy. #SleepAwarenessWeek #SleepWeek2024
-
Inspire® therapy is changing the game for those with obstructive sleep apnea. Our CEO, Tim Herbert, spoke with the Star Tribune about the demand for the device and how it’s changing lives. https://bit.ly/42kTf0D Individual Results may vary. Inspire Upper Airway Stimulator: Moderate to severe OSA. RxOnly. Ages 18+. Failure of, or inability to use, CPAP required. For safety information, visit http://bit.ly/Safety-Info.
-
Becky Buddenbohm (Idaho Falls) and Kyle Isakson (Butte, Montana) are finding relief for their obstructive sleep apnea with Inspire. Their doctors say Inspire is a great alternative to those who cannot tolerate CPAP. Check out the story in the October/November edition of Montana Senior News. https://bit.ly/3RurKxX Individual Results may vary. Inspire Upper Airway Stimulator: Moderate to severe OSA. RxOnly. Ages 18+. Failure of, or inability to use, CPAP required. For safety information, or for specific criteria for pediatric use, visit http://bit.ly/Safety-Info
Montana Senior News/Idaho Senior Independent - Surgical Implant Offers Effective Alternative to CPAP
-
Elliott Dougherty was one of the first pediatric Down syndrome patients to receive Inspire during a clinical trial a few years ago after not sleeping well with CPAP. Elliott is now getting quality sleep, can concentrate better and has more confidence in school. Check out the full story! WGEM TV https://bit.ly/3N4oBCm Inspire was FDA approved for children with Down syndrome in March 2023, for those who cannot use CPAP, are aged 13-18 and have an AHI between 10-50. Individual Results may vary. Inspire Upper Airway Stimulator: Moderate to severe OSA. RxOnly. Ages 18+. Failure of, or inability to use, CPAP required. For safety information, or for specific criteria for pediatric use, visit http://bit.ly/Safety-Info
Down Syndrome Awareness Month highlights medical breakthrough for one Tri-State family
-
Congrats to our 2023 graduates! Inspire is committed to investing in our employees and their professional development. To learn more about how we are supporting team member development and demonstrating our commitment to transparency and sustainability, please see our updated ESG report https://bit.ly/3NN0ecp
-
Dick Murray and Ed Schoonmaker share more than a fence in Columbus, Ohio. The friends and neighbors also treat their obstructive sleep apnea the same way. Check out their stories and why they both turned to Inspire! https://bit.ly/49UhqX1 Individual Results may vary. Inspire Upper Airway Stimulator: Moderate to severe OSA. RxOnly. Ages 18+. Failure of, or inability to use, CPAP required. For safety information, or for specific criteria for pediatric use, visit http://bit.ly/Safety-Info
Spectrum News 1: Changes in sleep apnea treatments open doors for patients - Columbus, Ohio
spectrumnews1.com
-
Help us in celebrating Dr. Chio’s 600th implant milestone and hear what he has to say about Inspire: “I’m proud to be a part of such an exciting therapy, helping patients treat a difficult medical condition. I have an amazing team around me to make this possible and hope to further contribute to this emerging field.” – Dr. Chio
Similar pages
Browse jobs
Stock
INSP
NYSE
20 minutes delay
$237.45
6.44 (2.788%)
- Open
- 234.44
- Low
- 233.57
- High
- 244.8
Data from Refinitiv
See more info on